 |
Biosketch
Dr. Schiff is Clinical Professor of Medicine, Rheumatology Division, University of Colorado School of Medicine, Denver, Colorado. Dr. Schiff is board certified in Internal Medicine and Rheumatology. He has received a number of Outstanding Clinical Facility awards from the University Of Colorado School Of Medicine, including the Academic Publications Award and the Research Project Award. Dr.... Display Full Bio
Affiliations
- Director of Clinical Research
Denver Arthritis Clinic
University of Colorado
|
Activities involving Michael H. Schiff
1 result
 Released: Nov 15, 2007
Expires: Nov 15, 2008
Type: PDF
Currently, three tumor necrosis factor (TNF) antagonists are approved for the treatment of patients with rheumatoid arthritis (RA): infliximab, etanercept, and adalimumab. Whilst, overall, TNF antagonists are well tolerated and have demonstrated a favorable risk–benefit profile, there are lingering concerns over their long-term safety. For example, data from clinical trials...
|
- CME Credits/Hours: 2.00
- Cost: Free
-
System Requirements:
|
|
